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Although it is well appreciated that arachidonic acid,
a second messenger molecule that is released by ligand-
stimulated phospholipase A2, stimulates a wide range of
cell types, the mechanisms that mediate the actions of
arachidonic acid are still poorly understood. We now
report that arachidonic acid stimulated the appearance
of dual-phosphorylated (active) p38 mitogen-activated
protein kinase as detected by Western blotting in HeLa
cells, HL60 cells, human neutrophils, and human umbil-
ical vein endothelial cells but not Jurkat cells. An in-
crease in p38 kinase activity caused by arachidonic acid
was also observed. Further studies with neutrophils
show that the stimulation of p38 dual phosphorylation
by arachidonic acid was transient, peaking at 5 min, and
was concentration-dependent. The effect of arachidonic
acid was not affected by either nordihydroguaiaretic
acid, an inhibitor of the 5-, 12-, and 15-lipoxygenases or
by indomethacin, an inhibitor of cyclooxygenase.
Arachidonic acid also stimulated the phosphorylation
and/or activity of the extracellular signal-regulated pro-
tein kinase and of c-jun N-terminal kinase in a cell-type-
specific manner. An examination of the mechanisms
through which arachidonic acid stimulated the phos-
phorylation/activity of p38 and extracellular signal-reg-
ulated protein kinase in neutrophils revealed an in-
volvement of protein kinase C. Thus, arachidonic acid
stimulated the translocation of protein kinase C a, bI,
and bII to a particulate fraction, and the effects of arachi-
donic acid on mitogen-activated protein kinase phospho-
rylation/activity were partially inhibited by GF109203X,
an inhibitor of protein kinase C. This study is the first to
demonstrate that a polyunsaturated fatty acid causes the
dual phosphorylation and activation of p38.
Arachidonic acid (20:4v6)1 is a second messenger that is
released by the action of phospholipase A2 in activated cells (1).
In in vitro assays, 20:4v6 and other polyunsaturated fatty acids
have been demonstrated to stimulate the activity of protein
kinase C (PKC) (2, 3). When added exogenously, 20:4v6 is
biologically active in a wide spectrum of cells. For example,
20:4v6 has been reported to inhibit gap junctional permeability
between adherent cells (4); stimulate superoxide production
and degranulation and increase the expression of CD11b/CD18
in human neutrophils (5–7), prime macrophages, and mono-
cytes for enhanced respiratory burst (8); stimulate insulin se-
cretion from isolated islets of Langerhans (9); modulate the
permeability of K1, Na1, and H1 channels in a variety of cell
types (10–12); stimulate gene transcription (13); and cause
differentiation and death (14). However, the molecular mech-
anisms through which the actions of 20:4v6 are mediated are
poorly understood.
We have previously demonstrated that 20:4v6 and other
polyunsaturated fatty acids stimulate the activity of the extra-
cellular signal-regulated protein kinase (ERK) in WB rat liver
epithelial cells (15), suggesting that ERK may mediate some of
the biological actions of polyunsaturated fatty acids. Others
have reported that arachidonic acid and its metabolites stim-
ulate ERK activity in smooth muscle cells (16). ERK and the
closely related p38 and jun N-terminal kinase (JNK) are mem-
bers of the mitogen-activated protein (MAP) kinase family of
kinases (17). These kinases are activated when cells are ex-
posed to growth factors, cytokines, and/or various forms of
stress (17, 18). Activation of ERK, JNK, and p38 MAP kinases
are achieved through the dual phosphorylation of threonine
and tyrosine residues in the TXY motif by upstream MAP
kinase kinases. MAP kinases have been proposed to regulate a
diverse range of biological functions, including cytokine pro-
duction and cell growth, differentiation, and death (17, 18).
Although 20:4v6 has recently been reported to stimulate the
activity of JNK in proximal tubular epithelial cells and in
stromal cells (19, 20), we are not aware of any studies that have
investigated whether 20:4v6 affects the activity of p38. We now
report the novel finding that 20:4v6 stimulated the dual phos-
phorylation of p38 in HeLa cells, HL60 cells, human umbilical
vein endothelial cells, and human neutrophils but not in Jurkat
T cells. Further characterization in neutrophils demonstrated
that 20:4v6 also stimulated the phosphorylation/activity of
ERK but not of JNK, although the activity of JNK was weakly
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stimulated by 20:4v6 in Jurkat cells. 20:4v6 also stimulated the
translocation of a number of PKC isozymes to a particulate frac-
tion in neutrophils. The effect of 20:4v6 on p38 and ERK dual
phosphorylation/activity was partially blocked by GF109203X, a
specific inhibitor of PKC. These data demonstrate that the ability
of 20:4v6 to stimulate the activity of p38 and JNK is cell type-
dependent and suggest that p38, ERK, JNK, and PKC are
potential mediators of the biological actions of 20:4v6.
EXPERIMENTAL PROCEDURES
Materials
Fatty acids, 20:4v6, formyl-methionyl-leucyl-phenylalanine, phorbol
12-myristate 13-acetate (PMA), myelin basic protein, kinase A peptide
inhibitor, protein A-Sepharose, and general reagents for kinase assays
were from Sigma. [g-32P]ATP (specific activity 4000 Ci/mmol) was ob-
tained from Bresatec, Adelaide, Australia. The anti-ERK antibody, R2,
was a kind gift from Dr. S. Pelech, University of British Columbia, or
was purchased from Upstate Biotechnology, Inc., Lake Placid, NY.
Rabbit anti-p38 and anti-JNK1 antibodies were obtained from Santa
Cruz Biotech. The anti-ACTIVETM ERK and p38 antibodies were ob-
tained from Promega Inc., Santa Cruz, CA. Enhanced chemilumines-
cence (ECL) solutions and reinforced nitrocellulose were from NEN Life
Science Products and Schleicher and Schuell, respectively. Glutathione-
Sepharose beads was from Pharmacia Biotech, Australia. Fatty acids,
PMA, and formyl-methionyl-leucyl-phenylalanine were dissolved in
ethanol, dimethyl sulfoxide (Me2SO), and Me2SO, respectively. The
final concentrations of the vehicles were: ethanol, 0.1% (v/v) and
Me2SO, 0.1% (v/v). Control cells received vehicle(s) alone.
Cell Culture
HeLa cells were maintained in Dulbeco’s modified Eagle’s medium in
the presence of fetal calf serum (10%) and antibiotics as described
previously (21). Cells (0.25 3 106) were plated in 10-cm culture dishes
and were used after 4 days. HL60 and Jurkat T cells were maintained
in RPMI 1640 supplemented fetal calf serum with and antibiotics at
#1 3 106/ml. All cells were washed once with Hanks’ balanced salts
solution (HBSS) 30 min before being incubated with 20:4v6 or vehicle.
Isolation and Incubation of Neutrophils
Human neutrophils were isolated from the peripheral blood of
healthy volunteers by the rapid single-step method of Ferrante and
Thong (22). The preparation of neutrophils was of .98% purity and
.99% viability as judged by morphological examination of cytospin prep-
arations and the ability of viable cells to exclude trypan blue. Cells in
HBSS were incubated in the presence of 20:4v6 for the times indicated.
Preparation of Cellular Extracts
Incubations were terminated by removing the incubation medium
and washing the cells once with HBSS (4 °C).
p38 and JNK—For p38 and JNK assays, cells were lysed in 150 ml of
buffer A (20 mM Hepes, pH 7.4, 0.5% (v/v) Nonidet P-40, 100 mM NaCl,
1 mM EDTA, 2 mM, 2 mM Na3VO4, 2 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride, and 10 mg/ml leupeptin, aprotinin, pepstatin A,
and benzamidine) for 2 h at 4 °C. After centrifugation (16,000 3 g, 5
min), the supernatants were collected for kinase assay or for Western
blotting as described below.
ERK—Activation of ERK was determined by a kinase assay and by
Western blotting. Pelleted cells were sonicated (3 3 10 s, output of 2
units, Soniprobe) in buffer B (25 mM Tris-HCl, pH 7.5, 2 mM EGTA, 25
mM NaCl, 1 mM Na3VO4, 38 mM p-nitrophenylphosphate, 10 mg/ml
pepstatin A, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 0.2 mM phenyl-
methylsulfonyl fluoride, and 1 mM dithiothreitol) and centrifuged
(100,000 3 g, 20 min), and the supernatants (termed cytosolic fractions)
were collected for Western blotting as described below or for kinase assay.
Before the kinase assay, cytosolic fractions were batch-adsorbed onto
phenyl-Sepharose CL4B. After washing the beads with 10% (23) and 35%
(23) ethylene glycol in buffer A (v/v), ERK was eluted with 60% ethylene
glycol (23). Previous studies have demonstrated that phenyl-Sepharose-
adsorbed ERK1 and ERK2 are eluted between 35 and 60% ethylene glycol
(23). The activity of ERK was assayed as described below.
PKC—To study PKC translocation, neutrophils were sonicated in
buffer C (25 mM Tris-HCl, pH 7.5, containing 1 mM dithiothreitol, 5 mM
EGTA, 2 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, and 10 mg/ml
leupeptin, aprotinin, pepstatin A, and benzamidine). After incubating
on ice for 30 min, samples were centrifuged (100,000 3 g, 30 min), and
the pellets were resuspended in Buffer C containing 2% Triton X-100.
After a 30-min incubation on ice, samples were centrifuged (100,000 3
g, 30 min), the supernatant was mixed with Laemmli buffer, and PKC
isozymes were separated by SDS-polyacrylamide gel electrophoresis
and immunoblotted with isozyme-specific anti-PKC antibodies as de-
scribed below.
Kinase Assays
p38—p38 was immunoprecipitated before determination of kinase
activity. Briefly, lysates (700 mg of protein) were precleared with pro-
tein A-Sepharose (15 ml/sample). Anti-p38 antibody (3 mg/sample) was
added, and tubes were incubated with constant mixing for 90 min at
4 °C. The antigen-antibody complexes were precipitated by the addition
of protein A-Sepharose (20 ml/sample). The immunoprecipitates were
washed once with buffer A and once with assay buffer (20 mM Hepes,
pH 7.2, 20 mM b-glycerophosphate, 3.8 mM p-nitrophenyl phosphate, 10
mM MgCl2, 1 mM dithiothreitol, 50 mM Na3VO4, and 20 mM ATP) at 4 °C.
The assay was started by adding 30 ml of assay buffer (30 °C) containing
10 mCi of g32P-ATP, 3.8 mM p-nitrophenylphosphate, and 15 mg of
myelin basic protein. After 15 min, the assay was terminated by the
addition of Laemmli buffer and boiling the samples for 5 min at 100 °C.
Phosphorylated myelin basic protein was resolved by 12% SDS-poly-
acrylamide gel electrophoresis and was detected and quantitated using
an Instant Imager (Packard Instruments).
JNK—A solid phase assay was used to assay JNK activity as de-
scribed previously (24). Briefly, glutathione S-transferase-jun (1–79)
fusion protein was purified from bacterial lysates using glutathione-
Sepharose beads at 4 °C with gentle rocking. 1 mg of lysate protein, 15
mM MgCl2, and 10 mM ATP were added to 25 ml (packed volume) of
glutathione S-transferase-jun (1–79) coupled to glutathione-Sepharose
beads. The mixtures were incubated for 2 h at 4 °C with gentle rocking.
After centrifugation (16,000 3 g, 5 min), the beads were washed once
with buffer A, once with wash buffer (10 mM Pipes, pH 7, 100 mM NaCl,
and the protease inhibitors, which were added to buffer A) and once
with assay buffer (see p38 above). The assay was started by adding 35
ml assay buffer containing 8 mCi of g32P-ATP and bringing the temper-
ature to 30 °C. After 20 min, the assay was terminated by the addition
of Laemmli buffer and boiling the samples for 5 min at 100 °C. Samples
were resolved by 10% SDS-polyacrylamide gel electrophoresis, and
detection and quantitation of phosphorylated glutathione S-transfer-
ase-jun (1–79) was as described above.
ERK—ERK activity was assayed as described previously (12, 23) by
monitoring the incorporation of 32Pi into myelin basic protein in the
presence of EGTA and protein kinase A peptide inhibitor. The assay
mixture did not contain added phospholipids. Assays were terminated
by spotting aliquots of the reaction mixture onto P81 filter paper. After
3 washes (5 min each) with 75 mM orthophosphoric acid, radioactivity
associated with the paper was determined by liquid scintillation spec-
trometry. There was no detectable protein kinase A activity in phenyl-
Sepharose-purified fractions, since omission of the protein kinase A
peptide inhibitor from the assay mixture did not result in increased
phosphorylation of myelin basic protein (Ref. 23 and data not shown).
Active p38, if present in the fractions, was unlikely to contribute to any
significant degree toward the total myelin basic protein kinase activity
because the time course of ERK activity did not correlate with the
appearance of dual-phosphorylated p38 (see “Results”). Consequently,
it is unlikely that PKC, Ca21/calmodulin-dependent kinases, p38, or
protein kinase A were responsible for phosphorylating myelin basic
protein in these samples.
Western Blotting
Denatured proteins were separated on either 10 (ERK and p38) or
12% (PKC) polyacrylamide gels and transferred to nitrocellulose (100 V,
1.5 h), and immunoreaction and detection were carried out as described
earlier (25). Immediately after transfer, blots were stained with Pon-
ceau S (0.1% in 5% acetic acid) to confirm equal loading of all lanes of
the gels. Affinity-purified polyclonal anti-ERK antibody, R2, anti-AC-
TIVETM ERK, or anti-ACTIVETM p38 antibody and anti-PKC isozyme-
specific antibodies were used to detect ERK isoforms, dual-phosphoryl-
ated ERK, dual phosphorylated p38, and PKC isozymes, respectively.
Immunocomplexes were detected by enhanced chemiluminescence (25).
Statistical Analysis
Where appropriate, differences were analyzed by analysis of variance
or unpaired Student’s t test and were considered significant when p ,
0.05.
Activation of MAP Kinases by Arachidonic Acid19278
RESULTS
Incubation of HeLa cells, HL60 cells, and human neutrophils
with 20:4v6 (20 mM) for 4 min resulted in the dual phosphoryl-
ation of p38 as detected by Western blotting (Fig. 1). Similar
results were obtained in human umbilical vein endothelial cells
(data not shown). Ponceau S staining confirmed that, within a
particular experiment, the individual lanes were loaded with
equal amounts of proteins (data not shown). Since the anti-
ACTIVE™ p38 antibody only detects p38 that had been dual
phosphorylated on the TGY activation motif, these results in-
dicate activation of p38 by 20:4v6. Kinase activity assays in
neutrophils confirmed this (Fig. 1). In contrast to the above
data, 20:4v6 did not enhance p38 dual phosphorylation in
Jurkat cells (data not shown) that express p38 (26).
Our previous studies in human neutrophils have demon-
strated that 20:4v6 stimulated superoxide production, degran-
ulation, and adherence to plastic surfaces and increased the
expression of CD11b/CD18 (5–7). To elucidate the mechanisms
through which 20:4v6 exerted these actions, the effects of 20:
4v6 on MAP kinases were studied in more detail in the neu-
trophils. 20:4v6 stimulated the dual phosphorylation of p38 in
a concentration- and time-dependent manner (Fig. 2). Thus,
dual-phosphorylated p38 could be detected at 5 mM 20:4v6, and
phosphorylation increased with increasing concentrations of
20:4v6 up to 20 mM, the maximum concentration tested (Fig.
2a). Stimulation of p38 dual phosphorylation, detectable at less
than 2 min, was transient, peaking at 5 min after exposure to
20:4v6 (Fig. 2b). Very little dual-phosphorylated p38 was left at
10 min after the addition of 20:4v6. The ability of 20:4v6 to
stimulate dual phosphorylation of p38 was not diminished by
either nordihydroguaiaretic acid, a broad spectrum inhibitor of
the 5-, 12-, and 15-lipoxygenase or by indomethacin, an inhib-
itor of cyclooxygenase (Fig. 3). A small amount of dual-phos-
phorylated p38 was detected in neutrophils that had been
exposed to either nordihydroguaiaretic acid or indomethacin
per se. This was likely to be due to the accumulation of low
levels of endogenous 20:4v6 in the presence of nordihydroguai-
aretic acid or indomethacin.
We next examined whether 20:4v6 also stimulated the ac-
tivity of JNK in human neutrophils. Although 20:4v6 has been
reported to stimulate the activity of JNK in stromal and rabbit
proximal tubular epithelial cells (19, 20), the fatty acid did not
stimulate JNK activity in neutrophils (data not shown). This
was not because neutrophils do not express JNK, because the
presence of JNK1 was detected in neutrophils (data not
shown). However, 20:4v6 stimulated the activity of JNK in
Jurkat T cells (Fig. 4), although the degree of activation was
less than that observed with A23187/PMA (Fig. 4). v3 fatty
acids also stimulated JNK activity in Jurkat cells (data not
shown).
Although we have previously demonstrated that 20:4v6
stimulated the activity of ERK in WB rat liver cells (12), the
effect of 20:4v6 on ERK activity in neutrophils has not been
reported. Because the above data demonstrate that 20:4v6
stimulated the dual phosphorylation of p38 and the activity of
JNK in a cell type-specific manner, it is, therefore, important to
determine whether the activity of ERK in neutrophils is af-
fected by 20:4v6. Activated ERK isoforms display reduced elec-
trophoretic mobility in SDS-polyacrylamide gels (12, 21, 25, 27)
because of the dual phosphorylation of ERK on the TEY acti-
vation motif. Incubation of neutrophils with 20:4v6 caused a
retardation in the electrophoretic mobility of the 42- and 43-
kDa forms of ERK to give apparent Mr values of 43- and 44-kDa
FIG. 1. Stimulation of p38 dual phosphorylation and activity
by 20:4v6. HeLa cells (4 3 106 cells), HL60 cells (2 3 107 cells), and
neutrophils (3 3 107 cells) were incubated with 20:4v6 (20 mM) for 4 min
at 37 °C and lysed. Fractions were prepared and Western blotted with
anti-ACTIVETM p38 antibody (a). In some experiments with neutro-
phils, kinase activity was also determined using myelin basic protein as
a substrate (b), as described under “Experimental Procedures.” Results
are representative of 3–4 separate experiments.
FIG. 2. Characteristics of 20:4v6-stimulated p38 dual phospho-
rylation. Neutrophils were incubated with 20:4v6 at the concentra-
tions indicated for 4 min (a) or with 20:4v6 (20 mM) for up to 10 min (b).
Cells were lysed and the fractions were Western-blotted as described
under “Experimental Procedures.” The results are representative of at
least three experiments.
FIG. 3. Lack of effect of nordihydroguaiaretic acid or indo-
methacin on the appearance of dual phosphorylated p38. Neu-
trophils were preincubated for 10 min with either nordihydroguaiaretic
acid (NDGA) (10 mM) or indomethacin (100 mM) before being exposed to
20:4v6. Samples were prepared and Western blotted as described under
“Experimental Procedures.” The results are representative of three
experiments.
FIG. 4. 20:4v6 stimulated the activity of JNK in Jurkat cells.
Jurkat cells were stimulated with 0–20 mM 20:4v6 (a), with 0–10 mM
A23178 and 35 nM PMA (b) for 30 min, or with 20:4v6 (10 mM) or A23187
(1 mM)/PMA (35 nM) for up to 120 min (c). The cells were lysed, and JNK
activity was assayed as described under “Experimental Procedures.”
Results of the time course experiments (c) are expressed as cpm 32Pi
incorporated into glutathione S-transferase jun (1–79). Results are
representative of three separate experiments.
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(Fig. 5a), consistent with their activation by phosphorylation.
When the fractions were Western-blotted with anti-ACTIVETM
ERK antibody that detects active, dual-phosphorylated ERK,
two bands with Mr values of approximately 43-and 44-kDa
were detected predominantly in samples from 20:4v6-stimu-
lated cells (Fig. 5b). Kinase assays demonstrate that the en-
hancement of ERK activity by 20:4v6 was concentration-de-
pendent. An increase in kinase activity was detectable at 5 mM
20:4v6, the lowest concentration tested (Fig. 6a). The effect of
20:4v6 peaked at around 15 min after the addition of 20:4v6
(Fig. 6b) and was longer lasting than stimulation of p38 dual
phosphorylation or activity (Fig. 2b). This argues strongly
against the possibility that contaminating p38, which also
phosphorylates myelin basic protein (Fig. 1b), was responsible
for phosphorylating myelin basic protein in these fractions,
since the appearance of dual-phosphorylated p38 peaked at 5
min after the addition of 20:4v6 and declined rapidly thereaf-
ter. 20:4v6 also stimulated the activity of ERK in human
umbilical vein endothelial cells, human mesangial cells, Jurkat
cells, HL60 cells, and human monocytes but not in PC12 phe-
ochromocytoma cells (data not shown). The activity of ERK in
these cells was also stimulated by the v3 fatty acids, eicosap-
entaenoic acid (20:5v3) and docosahexaenoic acid (22:6v3)
(data not shown).
Since polyunsaturated fatty acids have been demonstrated to
activate PKC in vitro (2, 3) and to stimulate the translocation
of PKC in WB rat liver epithelial cells (12), we investigated
whether PKC was involved in the activation of the p38 and
ERK cascades by 20:4v6 in neutrophils. Neutrophils contain
PKC a, bI, bII, d, and z (28). Although polyunsaturated fatty
acids have been reported to stimulate Ca21 mobilization (29),
activate the neutral sphingomyelinase (30), and amplify H1 ion
channel conductance (31) in intact neutrophils and to stimulate
GTPgS loading of the heterotrimeric G-proteins in neutrophil
membrane fractions (32), the effect of fatty acids on PKC trans-
location in neutrophils has not been reported. In unstimulated
neutrophils, a substantial amount of PKC bII was detected in
a particulate fraction, and this was increased after incubation
with 20:4v6 (Fig. 7). The existence of particulate fraction-
associated PKC in unstimulated cells has also been observed in
the T lymphocyte cell line, CTLL-2 (33). 20:4v6 also caused a
small amount of PKC a and bI to associate with the particulate
fraction (Fig. 7). Neither PKC d nor z was detected in the
particulate fraction (data not shown). An involvement of PKC
in the activation of MAP kinases by 20:4v6 was confirmed by
the observation that GF109203X, an inhibitor of classical PKC
isozymes (34), attenuated the stimulatory effect of 20:4v6 on
ERK activity by .85% (Fig. 8a). GF109203X also caused a
modest reduction in the ability of 20:4v6 to stimulate the
appearance of dual-phosphorylated p38 (Fig. 8b).
DISCUSSION
20:4v6 is a second messenger molecule that is liberated from
the sn-2 position of membrane phospholipids by ligand-stimu-
lated activation of the cytosolic phospholipase A2 (1). The im-
portance of endogenously generated 20:4v6 in ligand-stimu-
lated responses has been adequately demonstrated using
inhibitors of cytosolic phospholipase A2 and antisense technol-
ogy (1). The non-esterified 20:4v6 that is released has been
found to be cell-associated as well as being released into the
extracellular medium. Thus, many studies have assayed for the
appearance of radiolabeled 20:4v6 in the extracellular medium
as a measure of phospholipase A2 activation (1, 35, 36). Al-
though cell-associated 20:4v6 can directly serve as an endoge-
nous second messenger and is a substrate for the lipoxygenases
and cyclooxygenases, 20:4v6 that is released into the extracel-
lular fluid has the potential to exert autocrine and paracrine
effects. Consistent with this suggestion, exogenously added
FIG. 5. Stimulation of ERK phosphorylation by 20:4v6 in hu-
man neutrophils. Neutrophils (3 3 107 cells in 30 ml of HBSS) were
stimulated with 20:4v6 (20 mM, 10 min), formyl-methionyl-leucyl-phe-
nylalanine (50 nM, 5 min), or PMA (100 nM, 5 min). Cytosolic fractions
were prepared and Western-blotted with the anti-ERK antibody, R2 (a),
or with the anti-ACTIVETM ERK antibody (b) as described under “Ex-
perimental Procedures.” a: lane 1, control; lane 2, formyl-methionyl-
leucyl-phenylalanine; lane 3, 20:4v6; lane 4, PMA. b: lane 1, control;
lane 2, 20:4v6. Results are representative of at least three experiments.
FIG. 6. The activity of ERK in neutrophils was stimulated in a
concentration- and time-dependent manner by 20:4v6. Neutro-
phils were incubated with 20:4v6 at the concentrations indicated for 10
min (a) or for the times indicated (b, control (E); 20 mM 20:4v6 (l )). ERK
in cytosolic fractions was partially purified, and the activity was as-
sayed as described under “Experimental Procedures.” Results are the
mean 6 S.E. of three determinations (a) or the mean of duplicate
determinations (b). Results are representative of at least three
experiments.
FIG. 7. 20:4v6 stimulated the translocation of PKCa, bI, and
bII. Neutrophils were stimulated with 20:4v6 (20 mM) for 3 min, and
PKC fractions were prepared and Western-blotted as described under
“Experimental Procedures.” The results are representative of three
experiments.
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20:4v6 has been shown to be biologically active to a wide
spectrum of cell types at concentrations (1–20 mM) that have
been reported to be present in stimulated cells. Thus, neutro-
phils have been reported to contain 100–2,200 pmol/107 cells of
20:4v6, and in isolated islets of Langerhans, glucose was found
to increase cell-associated nonesterified 20:4v6 by up to 75 mM
(37, 38). However, the mechanisms through which 20:4v6 act
are still poorly understood.
The present study demonstrates that exogenous 20:4v6
stimulated the dual phosphorylation of p38 in HeLa cells,
HL60 cells, human neutrophils, and human umbilical vein
endothelial cells but not in Jurkat cells. We demonstrate in
neutrophils that this increase in p38 dual phosphorylation was
accompanied by an increase in p38 kinase activity. Stimulation
of p38 dual phosphorylation by 20:4v6 in neutrophils was in-
dependent of its metabolism by either lipoxygenase or cyclooxy-
genase since the effect was not affected by nordihydroguaia-
retic acid, a broad spectrum inhibitor of the 5-, 12-, and
15-lipoxygenases or by indomethacin, an inhibitor of cyclooxy-
genase. The fatty acid also stimulated the dual phosphoryla-
tion and activity of ERK but not of JNK in neutrophils. This,
therefore, excludes an involvement of JNK in the actions of
20:4v6 in the neutrophils. However, 20:4v6 stimulated the
activity of JNK in Jurkat T cells, an observation that is con-
sistent with reports in proximal tubular epithelial cells and
stromal cells that the activity of JNK was stimulated by 20:4v6
(19, 20). The ability of 20:4v6 to stimulate the activity of ERK
in human neutrophils and a number of other primary cell types
and cell lines is consistent with our previous observations in
WB rat liver epithelial cells (15). However, 20:4v6 did not affect
the activity of ERK in PC12 cells, although ERK activity in
these cells was strongly stimulated by PMA.2 These data,
therefore, demonstrate that 20:4v6 stimulated the activity of
MAP kinases in a cell type/line-specific manner.
The present study demonstrates that PKC may be involved,
at least in part, in mediating the effects of 20:4v6 on p38 and
ERK activation. Thus, 20:4v6 not only stimulated the translo-
cation of PKC a, bI, and bII to a particulate fraction in neu-
trophils, but the effects of 20:4v6 on p38 dual phosphorylation
and ERK activity were attenuated by the PKC inhibitor,
GF109203X. Consistent with a possible involvement of PKC in
the p38 and ERK cascades, PMA, a direct activator of PKC,
stimulates the activity of ERK in all cell types examined (18)
and of p38 in some cell types (39, 40). Recent studies have
revealed that at least four members of the p38 family exist.
These are p38a (also known as p38, CSBP, RK), p38b, p38g
(ERK6/SAPK3), and p38d (SAPK4) (41, 42). PMA selectively
stimulated the activity of p38g and p38d without significantly
affecting the activity of p38a or p38b (42), indicating that the g
and d forms of p38 are regulated by PKC. It remains to be
determined whether the PMA-responsive p38 in neutrophils
(39) and U937 cells (40) are p38g and/or p38d. Although PKC
may regulate the ERK cascade by direct phosphorylation of
raf-1 (43) or via Shc/Ras (44), it is currently not known how
PKC may regulate the p38 cascade.
In contrast to its effect on ERK activity, the effect of
GF109203X on p38 dual phosphorylation was partial. This
could imply that PKC is not the sole upstream regulator of the
p38 cascade. 20:4v6 has been reported to stimulate the release
of rho-GDI from its complex with rac2. guanine nucleotide
dissociation inhibitor (45), and constitutively active rac has
been found to stimulate the activity of p38 via p21-activated
kinase (46). Hence, the fatty acid may also activate p38 via
modulation of rac2 and p21-activated kinase, independently of
PKC. Alternatively, the partial inhibition could suggest the
possibility that neutrophils express both PKC-dependent and
independent p38 forms. Until specific antibodies to p38 sub-
types become available commercially, it is not possible to de-
termine which p38 form(s) is activated by 20:4v6.
Although GF109203X has been generally regarded as a spe-
cific PKC inhibitor, a recent study has found that GF109203X
also inhibited the activity of MAP kinase activated protein
kinase-1b (rsk-2) and p70 S6 kinase (47). However, the effects
of GF109203X on 20:4v6-stimulated ERK activity and p38 dual
phosphorylation were unlikely to be due to inhibition of rsk-2 or
p70 S6 kinase, since neither of these kinases are upstream
regulators of ERK or p38.
The inability of 20:4v6 to stimulate JNK activity in neutro-
phils is in direct contrast to the observations in stromal (20)
and proximal tubular epithelial cells (19). Although 20:4v6
stimulated the activity of JNK in Jurkat cells, this effect was
weak compared with that caused by A21387 and PMA. Our
failure to detect JNK activity was not because of a lack of JNK
expression in neutrophils. Studies in proximal tubular epithe-
lial cells have shown that stimulation of JNK activity by 20:4v6
requires activation of the NADPH oxidase (19). Given that
20:4v6 strongly stimulates the NADPH oxidase in neutrophils,
it is, therefore, surprising that the fatty acid failed to stimulate
the activity of JNK in neutrophils. This result clearly demon-
strates that generation of oxygen radicals per se is insufficient
to stimulate the JNK cascade.
Many ligands that stimulate the activity of MAP kinases also
stimulate the activity of cytosolic phospholipase A2. It has been
widely reported that ERK or p38 directly phosphorylates cyto-
solic phospholipase A2 in activated cells and in in vitro assays
(48, 49) and, with the exception of thrombin-stimulated plate-
lets (50), ERK or p38 has been found to directly regulate the
enzymatic activity of cytosolic phospholipase A2. Our study,
therefore, suggests that fatty acids such as 20:4v6, which are
liberated by ligand-stimulated cytosolic phospholipase A2, may
participate in sustaining/amplifying MAP kinase activity and
the activity of cytosolic phospholipase A2. Consistent with this,
exogenously added polyunsaturated fatty acids have been2 C. S. T. Hii and A. Ferrante, unpublished data.
FIG. 8. Inhibition of ERK activity and p38 phosphorylation by
GF109203X. Neutrophils (1 3 107 in 10 ml HBSS for ERK activity
assays, 3 3 107 in 30 ml HBSS for p38 phosphorylation) were preincu-
bated with GF109203X (0.5 mM, filled bars) or Me2SO (0.1% v/v, open
bars) for 10 min. The cells were then incubated with 20:4v6 (20 mM) for
10 (ERK activity assays) or 4 (for p38 phosphorylation) min. Determi-
nation of ERK activity (a) and p38 dual phosphorylation (b) were
carried out as described under “Experimental Procedures.” Data on
ERK activity are means 6 S.E. of three determinations. Results are
representative of three experiments. Significance of difference: * p ,
0.05.
Activation of MAP Kinases by Arachidonic Acid 19281
found to stimulate the activity of cytosolic phospholipase A2 in
intact neutrophils.3
It is currently not clear how fatty acids are taken up into
cells and exert their effects. There is evidence that indicates
that fatty acids enter cells by simple diffusion (51) and/or via a
carrier-mediated process. Proteins that function as fatty acid
transporters have been reported to exist on the plasma mem-
brane of a number of cell types (52, 53). It is possible that these
mechanisms are not mutually exclusive. Clearly, partititioning
of a fatty acid into the plasma membrane per se is insufficient
to exert a biological action (54, 55). A detergent-like action of
polyunsaturated fatty acids on the neutrophils has been ex-
cluded at concentrations that were used in this study (56). It is
also unlikely that the biological activities of a fatty acid are
dependent on esterification into membrane phospholipids,
since the effects of fatty acids are reversed after the addition of
delipidated serum albumin (4, 29) too rapidly to support an
esterification-based mechanism of action. A direct agonist-like
fatty acid action is therefore likely.
The present study establishes for the first time that 20:4v6
stimulates the dual phosphorylation of p38 MAP kinase and
that this stimulation is cell type-specific. Although this effect
was observed in HeLa cells, HL60 cells, human umbilical vein
endothelial cells, and human neutrophils, 20:4v6 did not in-
crease the amount of dual-phosphorylated p38 in Jurkat T
cells. Our studies also demonstrate that 20:4v6 stimulates the
activity of ERK and JNK. Again, this effect was cell type-
specific. Our data, therefore, suggest that ERK, p38, JNK, and
PKC are potential mediators of the biological actions of 20:4v6.
The MAP kinase species that is recruited will depend on the
cell type.
Acknowledgment—We thank Dr. S. L. Pelech, University of British
Columbia, Canada, for the gift of anti-ERK antibody, R2.
REFERENCES
1. Dennis, E. A. (1997) Trends Biochem. Sci. 22, 1–2
2. Murakami, K., and Routtenberg, A (1985) FEBS Lett. 192, 189–193
3. McPhail, L. C. Clayton, C. C., and Snyderman, R. (1984) Science 224, 622–625
4. Hii, C. S. T., Ferrante, A., Schmidt, S., Rathjen, D. A., Robinson, B. S., Poulos,
A and Murray, A. W. (1995) Carcinogenesis 16, 1505–1511
5. Poulos, A., Robinson, B. S., Ferrante, A., Harvey, D. P., Hardy, S. J., and
Murray, A. W. (1991) Immunology 73, 102–108
6. Bates, E. J., Ferrante, A., Smithers, L., Poulos, A., and Robinson, B. R. (1995)
Atherosclerosis 116, 247–259
7. Bates, E. J., Ferrante, A., Harvey, D. P., and Poulos, A. (1993) J. Leucocyte
Biol. 53, 420–426
8. Huang, Z. H., Hii, C. S. T., Rathjen, D. A., Poulos, A., Murray, A. W., and
Ferrante, A. (1997) Biochem. J. 325, 553–557
9. Band, A. M., Jones, P. J., and Howell, S. L. (1992) J. Mol. Endocrinol. 8,
95–101
10. Smirnov, S. V., and Aaronson, P. I. (1996) Circ. Res. 79, 20–31
11. Wieland, S. J., Gong, Q., Poblete, H., Fletcher, J. E., Chen, L. Q., and Kallen,
R. G. (1996) J. Biol. Chem. 271, 19037–19041
12. DeCoursey, T. E., and Cherny, V. V. (1993) Biophys. J. 65, 1590–1598
13. Clarke, S. D., and Jump, D. B. (1993) Prog. Lipid Res. 32, 139–149
14. Finstad, H. S., Kolset, S. O., Holme, J. A., Wiger, R., Farrants, A. K., Blomhoff,
R., and Drevon, C. A. (1994) Blood 84, 3799–3809
15. Hii, C. S. T., Ferrante, A., Edwards, Y., Huang, Z. H., Hartfield, P. J., Rathjen,
D. A., Poulos, A., and Murray, A. W. (1995) J. Biol. Chem. 270, 4201–4204
16. Rao, G. N., Baas, A. S., Glascow, W. C., Eling, T. E., Runge, M. S., and
Alexander, R. W. (1994) J. Biol. Chem. 269, 32586–32591
17. Kyriakis, J. M., and Avruch, J. (1996) J. Biol. Chem. 271, 24313–24316
18. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726–735
19. Cui, X. L., and Douglas, J. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94,
3771–3776
20. Rizzo, M. T., and Carlo-Stella, C. (1996) Blood 88, 3792–3800
21. Hii, C. S. T., Edwards, Y. S., and Murray, A. W. (1991) J. Biol. Chem. 266,
20238–20243
22. Ferrante, A., and Thong, Y. H. (1982) J. Immunol. Methods 48, 81–85
23. Anderson, N. G., Maller, J. L., Tonks, N. K., and Sturgill, T. W. (1990) Nature
343, 651–653
24. Sakata, N., Patel, H. R., Terada, N., Aruffo, A., Johnson, G. L., and Gelfand,
E. W. (1995) J. Biol. Chem. 270, 30823–30828
25. Hii, C. S. T., Oh, S. Y., Schmidt, S., Clark, K. J., and Murray, A. W. (1994)
Biochem. J. 303, 475–479
26. Crawley, J. B., Rawlinson, L., Lali, F. V., Page, T. H., Saklatvala, J., and
Foxwell, B. M. (1997) J. Biol. Chem. 272, 15023–15027
27. Guyton, K. Z., Liu, Y., Gorospe, M., Xu, Q., and Holbrook, N. J. (1996) J. Biol.
Chem. 271, 4138–4142
28. Smallwood, J. I., and Malawista, S. E. (1992) J. Leukocyte Biol. 51, 84–92
29. Hardy, S. J., Robinson, B. S., Ferrante. A., Hii, C. S. T., Johnson, D. W., Poulos,
A., and Murray, A. W. (1995) Biochem. J. 311, 689–697
30. Robinson, B. S., Hii, C. S. T., and Ferrante, A. (1997) Immunology 91, 274–280
31. Henderson, L. M., Banting, G., and Chappel, J. B. (1995) J. Biol. Chem. 270,
5909–5916
32. Abramson, S. B., Leszczynska-Piziak, J., and Weissman, G. (1991)
J. Immunol. 147, 231–236
33. Lu, Y., Tremblay, R., Jouishomme, H., Chakravarthy, B., and Durkin, J. P.
(1994) J. Immunol. 153, 1495–1504
34. Toullec, D., Pianetti, D., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane,
M., Baudet, V., Boissin, P., Boursier, E., Lorielle, F., Duhamel, L., Charon,
D., and Kirilovsky, J. (1991) J. Biol. Chem. 266, 15771–15781
35. Robinson, B. S., Hii, C. S. T., Poulos, A., and Ferrante, A. (1996) J. Lipid Res.
37, 1234–1245
36. Balsinde, J., and Dennis, E. A. (1996) J. Biol. Chem. 271, 6758–6765
37. Nichols, R. C., and Vanderhoek, J. Y. (1990) J. Exp. Med. 171, 367–375
38. Wolf, B. A., Turk, J., Sherman, W. R., and McDaniel, M. L. (1986) J. Biol.
Chem. 261, 3501–3511
39. El Benna, J., Han, J., Park, J. W., Schmid, E., Ulevitch, R. J., and Babior, B. M.
(1996) Arch. Biochem. Biophys. 334, 395–400
40. Franklin, C. C., and Kraft, A. S. (1997) J. Biol. Chem. 272, 16917–16923
41. Jiang, Y., Gram, H., Zhao, M., New, L., Gu, J., Feng, L., De Padova, F., Ulev-
itch, R. J., and Han, J. (1997) J. Biol. Chem. 272, 30122–30128
42. Kumar, S., McDonnell, P. C., Gum, R. J., Hand, A. T., Lee, J. C., and Young,
P. R. (1997) Biochem. Biophys. Res. Commun. 235, 533–538
43. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H.,
Finkenzeller, G., Marme, D., and Rapp, U. R (1993) Nature 364, 249–252
44. El-Shemerly, M. Y. M., Besser, D., Nagasawa, M., and Nagamine, Y. (1997)
J. Biol. Chem. 272, 30599–30602
45. Chuang, T. H., Bohl, B. P., and Bokoch, G. M. (1993) J. Biol. Chem. 268,
26206–26211
46. Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., and
Bokoch, G. M. (1995) J. Biol. Chem. 270, 23934–23936
47. Alessi, D. R. (1997) FEBS Lett. 402, 121–123
48. Lin, L. L., Wartmann, M., Lin, A. Y., Knopf, J. L., Seth, A., and Davis, R. J.
(1993) Cell 72, 269–278
49. Borsch-Huabold, A. G., Kramer, R. M., and Watson, S. P. (1997) Eur. J.
Biochem. 245, 751–759
50. Kramer, R. M., Roberts, E. F., Um, S. L., Borsch-Haubold, A. G., Watson, S. P.,
Fisher, M. J., and Jakubowski, J. A. (1996) J. Biol. Chem. 271, 27723–27729
51. Rose, H., Hennecke, T., and Kammermeier, H. (1990) J. Mol. Cell. Cardiol. 22,
883–892
52. Berk, P. D. (1996) Proc. Soc. Exp. Biol. Med. 212, 1–4
53. Vyska, K., Meyer, W., Stremmel, W., Notohamiprodjo, G., Minami, K.,
Machulla, H. J., Gleichmann, U., Meyer, H., and Korfer, R. (1991) Circ. Res.
69, 857–870
54. Anel, A., Richieri, G. V., and Kleinfeld, A. M. (1993) Biochemistry 32, 530–536
55. Steinbeck, M. J., Hegg, G. G., and Karnovsky, M. J. (1991) J. Biol. Chem. 266,
16336–16342
56. Corey, S. J., and Rosoff, P. M. (1991) J. Lab. Clin. Med. 118, 343–3513 B. S. Robinson, C. S. T. Hii, and A. Ferrante, unpublished data.
Activation of MAP Kinases by Arachidonic Acid19282
